Show simple item record

dc.contributor.authorTin, Mandy
dc.contributor.authorCho, Chi-Hin
dc.contributor.authorChan, Kelvin C.
dc.contributor.authorJames, Anthony
dc.contributor.authorKo, Joshua
dc.date.accessioned2008-06-04T08:52:09Z
dc.date.available2008-06-04T08:52:09Z
dc.date.issued2007
dc.identifier.citationCarcinogenesis, 28(6): 1347-1355
dc.identifier.issn0143-3334
dc.identifier.pmid17148504
dc.identifier.doi10.1093/carcin/bgl238
dc.identifier.urihttp://hdl.handle.net/2436/29433
dc.description.abstractAstragalus memebranaceus is used as immunomodulating agent in treating immunodeficiency diseases and to alleviate the adverse effects of chemotherapeutic drugs. In recent years, it has been proposed that Astragalus may possess anti-tumorigenic potential in certain cancer cell types. In this study, the anti-carcinogenic effects of Astragalus saponin extract were investigated in HT-29 human colon cancer cells and tumor xenograft. Our findings have shown that Astragalus saponins (AST) inhibit cell proliferation through accumulation in S phase and G2/M arrest, with concomitant suppression of p21 expression and inhibition of cyclin-dependent kinase activity. Besides, AST promotes apoptosis in HT-29 cells through caspase 3 activation and poly(ADP-ribose) polymerase cleavage, which is indicated by DNA fragmentation and nuclear chromatin condensation. Nevertheless, we also demonstrate the anti-tumorigenic effects of AST in vivo, of which the reduction of tumor volume as well as pro-apoptotic and anti-proliferative effects in HT-29 nude mice xenograft are comparable with that produced by the conventional chemotherapeutic drug 5-fluorouracil (5-FU). In addition, the side effects (body weight drop and mortality) associated with the drug combo 5-FU and oxaliplatin are not induced by AST. These results indicate that AST could be an effective chemotherapeutic agent in colon cancer treatment, which might also be used as an adjuvant in combination with other orthodox chemotherapeutic drugs to reduce the side effects of the latter compounds.
dc.language.isoen
dc.publisherOxford Journals
dc.relation.urlhttp://carcin.oxfordjournals.org/cgi/content/full/28/6/1347
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents
dc.subject.meshApoptosis
dc.subject.meshAstragalus Plant
dc.subject.meshColonic Neoplasms
dc.subject.meshHT29 Cells
dc.subject.meshHumans
dc.subject.meshMice
dc.subject.meshMice, Nude
dc.subject.meshSaponins
dc.subject.meshTransplantation, Heterologous
dc.subject.meshXenograft Model Antitumor Assays
dc.titleAstragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft.
dc.typeJournal article
dc.identifier.journalCarcinogenesis
html.description.abstractAstragalus memebranaceus is used as immunomodulating agent in treating immunodeficiency diseases and to alleviate the adverse effects of chemotherapeutic drugs. In recent years, it has been proposed that Astragalus may possess anti-tumorigenic potential in certain cancer cell types. In this study, the anti-carcinogenic effects of Astragalus saponin extract were investigated in HT-29 human colon cancer cells and tumor xenograft. Our findings have shown that Astragalus saponins (AST) inhibit cell proliferation through accumulation in S phase and G2/M arrest, with concomitant suppression of p21 expression and inhibition of cyclin-dependent kinase activity. Besides, AST promotes apoptosis in HT-29 cells through caspase 3 activation and poly(ADP-ribose) polymerase cleavage, which is indicated by DNA fragmentation and nuclear chromatin condensation. Nevertheless, we also demonstrate the anti-tumorigenic effects of AST in vivo, of which the reduction of tumor volume as well as pro-apoptotic and anti-proliferative effects in HT-29 nude mice xenograft are comparable with that produced by the conventional chemotherapeutic drug 5-fluorouracil (5-FU). In addition, the side effects (body weight drop and mortality) associated with the drug combo 5-FU and oxaliplatin are not induced by AST. These results indicate that AST could be an effective chemotherapeutic agent in colon cancer treatment, which might also be used as an adjuvant in combination with other orthodox chemotherapeutic drugs to reduce the side effects of the latter compounds.


This item appears in the following Collection(s)

Show simple item record